🇺🇸 fordadistrogene movaparvovec in United States
13 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 27 March 2025 – 27 March 2026
- Total reports: 13
Most-reported reactions
- Thrombotic Microangiopathy — 3 reports (23.08%)
- Off Label Use — 2 reports (15.38%)
- Acute Kidney Injury — 1 report (7.69%)
- Adverse Event — 1 report (7.69%)
- Anaphylactic Reaction — 1 report (7.69%)
- Blood Creatinine Abnormal — 1 report (7.69%)
- Decreased Appetite — 1 report (7.69%)
- Dehydration — 1 report (7.69%)
- Fall — 1 report (7.69%)
- Fatigue — 1 report (7.69%)
Other Rare Disease approved in United States
Frequently asked questions
Is fordadistrogene movaparvovec approved in United States?
fordadistrogene movaparvovec does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for fordadistrogene movaparvovec in United States?
Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.